NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000054278

Registered date:29/04/2024

Reduction in nocturnal urinary frequency and improvement of fatty liver in SGLT-2 inhibitors.

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedtype 2 diabetes
Date of first enrollment2024/04/28
Target sample size135
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Prescription of 20 mg of tofogliflozin in men and women with type 2 diabetes Prescription of 5 mg of dapagliflozin in men and women with type 2 diabetes Prescription of 10 mg of empagliflozin in men and women with type 2 diabetes

Outcome(s)

Primary OutcomeChange in the frequency of nocturnal urine (23:00-6:00)
Secondary OutcomeImprovement of fatty liver

Key inclusion & exclusion criteria

Age minimum30years-old
Age maximum100years-old
GenderMale and Female
Include criteria
Exclude criteriaInsulin users Type 1 diabetes Mental illness Liver cirrhosis Renal failure

Related Information

Contact

public contact
Name Tetsuya Kawahara
Address 2-5 Dairishinmachi, Moji, Kitakyushu Japan 800-0057
Telephone 0933911001
E-mail k-tetsuy@med.uoeh-u.ac.jp
Affiliation Shin Komonji Hospital Endocrinology and Diabetes
scientific contact
Name Tetsuya Kawahara
Address 2-5 Dairishinmachi, Moji, Kitakyushu
Telephone +81-93-391-1001
E-mail k-tetsuy@med.uoeh-u.ac.jp
Affiliation Shin Komonji Hospital Endocrinology and Diabetes